# Junta clínica — PT-pseudo_938ba8a478e6 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_938ba8a478e6",
  "pid": "PT-pseudo_938ba8a478e6",
  "task": 1,
  "psa": 7.9,
  "age": 65,
  "months": 1,
  "pirads": "4",
  "psad": 0.07,
  "psav": 2.6,
  "psap": 5.6,
  "vol": 123.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.76090467,
  "medhx": "Hypertension, COPD, Chronic kidney disease",
  "meds": "amlodipine, valsartan, metoprolol, tiotropium, salbutamol PRN",
  "notes": "PSA 7.9 ng/mL. PI-RADS 4. PSAD 0.07. Prostate volume 123 mL. csPCa 0.76.",
  "pmhx": [
    "Hypertension",
    "COPD",
    "Chronic kidney disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "78 kg",
    "height": "180 cm",
    "bmi": "24.1",
    "bp": "123/70 mmHg",
    "hr": "83 bpm",
    "smoking": "Non-smoker",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "16 Jan 2025",
  "enc_ref": "Dr. M. Jansen (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinician review requested due to escalating antigen levels alongside a previously confirmed malignant biopsy."
    },
    {
      "s": "History",
      "t": "Aged 65 and employed as an office administrator, the individual resides solo, with his nephew designated as next of kin. A married non-smoker, his initial workup commenced in late 2022 following an elevated antigen reading. Chronic conditions include hypertension, chronic obstructive pulmonary disease, and chronic kidney disease. Current pharmacotherapy encompasses amlodipine, valsartan, metoprolol, tiotropium, and salbutamol administered on an as-needed basis. Lower urinary tract complaints register at 8 on the IPSS scale, yet recreational cycling persists at roughly 30 kilometres three times weekly. Recent outpatient visits to gastroenterology for routine colonoscopy and to endocrinology for thyroid evaluation both returned negative findings. Aside from minor visual deficits necessitating large-print materials, systemic complaints, bone discomfort, and urinary blood are denied. Workplace and domestic environments present no notable stressors. Alcohol consumption remains low at two weekly units. The subject maintains full independence in daily routines. A systematic transrectal ultrasound biopsy performed in early 2023 yielded Gleason 4+3 pathology."
    },
    {
      "s": "Physical examination",
      "t": "DRE — consistency: smooth and firm; symmetry: preserved; nodularity: absent. General inspection reveals clear pulmonary fields and a regular cardiac rhythm aligning with his established cardiovascular baseline. Abdominal palpation demonstrates a soft, non-tender contour devoid of masses or organomegaly."
    }
  ],
  "occupation": "office administrator",
  "marital": "Married",
  "living": "Lives alone",
  "next_of_kin": "Nephew",
  "recent_other": [
    "Gastroenterology — surveillance colonoscopy",
    "Endocrine — thyroid screening"
  ],
  "alcohol": "2 units / week",
  "exercise": "Cycling 3x/week, ~30 km",
  "ipss": "IPSS score: 8/35 (moderate LUTS)",
  "admin": "Visual impairment: large-print correspondence requested.",
  "mri_hospital": "Tergooi MC",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_938ba8a478e6
Task: 1

Encounter: Urology - outpatient on 16 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 7.9 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.07 ng/mL²
  - PSA velocity: 2.6 ng/mL/yr
  - Prior PSA: 5.6 ng/mL
  - Prostate volume: 123.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.76090467 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, COPD, Chronic kidney disease
  - Problem list / PMHx: Hypertension, COPD, Chronic kidney disease
  - Current medication: amlodipine, valsartan, metoprolol, tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 7.9 ng/mL. PI-RADS 4. PSAD 0.07. Prostate volume 123 mL. csPCa 0.76.

Vitals: weight 78 kg, height 180 cm, BMI 24.1, BP 123/70 mmHg, HR 83 bpm. Smoking: Non-smoker.

Chief complaint: Clinician review requested due to escalating antigen levels alongside a previously confirmed malignant biopsy.

History: Aged 65 and employed as an office administrator, the individual resides solo, with his nephew designated as next of kin. A married non-smoker, his initial workup commenced in late 2022 following an elevated antigen reading. Chronic conditions include hypertension, chronic obstructive pulmonary disease, and chronic kidney disease. Current pharmacotherapy encompasses amlodipine, valsartan, metoprolol, tiotropium, and salbutamol administered on an as-needed basis. Lower urinary tract complaints register at 8 on the IPSS scale, yet recreational cycling persists at roughly 30 kilometres three times weekly. Recent outpatient visits to gastroenterology for routine colonoscopy and to endocrinology for thyroid evaluation both returned negative findings. Aside from minor visual deficits necessitating large-print materials, systemic complaints, bone discomfort, and urinary blood are denied. Workplace and domestic environments present no notable stressors. Alcohol consumption remains low at two weekly units. The subject maintains full independence in daily routines. A systematic transrectal ultrasound biopsy performed in early 2023 yielded Gleason 4+3 pathology.

Physical examination: DRE — consistency: smooth and firm; symmetry: preserved; nodularity: absent. General inspection reveals clear pulmonary fields and a regular cardiac rhythm aligning with his established cardiovascular baseline. Abdominal palpation demonstrates a soft, non-tender contour devoid of masses or organomegaly.

Patient info: office administrator; Married; Lives alone.
Next of kin: Nephew.

Lifestyle: alcohol 2 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 8/35 (moderate LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Endocrine — thyroid screening.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.55
  uncertainty  +/- 0.11 epistemic (95% band 0.34-0.77); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.94: PI-RADS 4, PSA 6.5, PSAD 0.11, age 64, DRE Normal -> DEFER (uncertain). He wrote: "Need initial ISUP grade and MRI in men on active surveillance."
  2. distance 0.96: PI-RADS 4, PSA 5.3, PSAD 0.092, age 65, DRE Normal -> BIOPSY (clear). He wrote: "P4 in 65 years old patient"
  3. distance 1.12: PI-RADS 4, PSA 8.4, PSAD 0.1, age 63, DRE Normal -> BIOPSY (uncertain). He wrote: "Patient on Active surveillance. Initial ISUP and MRI is needed."

PRECEDENT: BIOPSY (weighted vote 0.65 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI is mandated to confirm histological progression before a change in treatment strategy. A stable MRI (PRECISE 1-3) does not make a repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not decisive because the guideline makes the decision dependent on the MRI findings, which are not yet fully established. The precedent cited by Expert 1, which suggests biopsy based on prior positive biopsy and PI-RADS 4, may differ on the crucial factor of whether the patient is on active surveillance or if a confirmatory biopsy is due.

WHAT WE STILL NEED
The prior-biopsy status is documented as "Positive" in the panel, which is a key factor.
The documented Gleason grade or ISUP grade from the prior biopsy and the number and dates of biopsy sessions are needed to determine the appropriate management pathway.
The PSA value is 7.9 ng/mL, which is above the threshold of 3-10 ng/mL mentioned in the literature regarding repeat PSA testing.
The PI-RADS score is 4, which is a factor that interacts with the guideline regarding repeat biopsy.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the prior biopsy grade and surveillance status to determine the next step according to the EAU guidelines.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What is the management context, including the prior biopsy result (Gleason/ISUP), surveillance protocol status, and planned treatment?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented Gleason or ISUP grade from the prior biopsy?
  Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion size and zone is 18 x 14 x 16 mm in the right mid-gland peripheral zone. Extraprostatic extension is not mentioned. Comparison against an earlier study is new.
psa_trend
The serial PSA value trend is rising, with values at "Dec 2022" of "2.1", "Sep 2023" of "3.3", "May 2024" of "5.1", and "Jan 2025" of "7.9".
previous_notes
The management context includes the prior biopsy result as "established prostate carcinoma" with a serum prostate-specific antigen measured "6.4 ng/mL" on "26 Jul 2023", and the patient is not explicitly on a surveillance protocol with a confirmatory biopsy due.

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes provided sufficient context regarding the prior biopsy and surveillance status.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PSA value of "7.9 ng/mL" is above the threshold of "3-10 ng/mL" mentioned in the literature regarding repeat PSA testing.
PI-RADS score of "4" is a factor that interacts with the guideline regarding repeat biopsy.
Findings that argue AGAINST sampling this patient now:
The prior biopsy result is documented as "established prostate carcinoma" without a specific Gleason/ISUP grade mentioned in the retrieved notes.
The previous notes do not explicitly state the patient is on a surveillance protocol with a confirmatory biopsy due.

WHERE THIS LEANS
The data suggests that the rising PSA and PI-RADS 4 finding warrant further investigation, but the lack of explicit surveillance status and prior grade leaves the next step ambiguous.
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 7.90 ng/mL over 4 points spanning 25 months; velocity +2.76 ng/mL per year; doubling time about 13 months.
PROJECTION at 6 months: 11.9 ng/mL, conformal 95% band 3.4-41.3.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.54
  uncertainty  +/- 0.10 epistemic (95% band 0.35-0.74), of which 0.01 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.55  ('discuss' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.54  ('discuss' tier, fusion_nolab)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.65  (k=3 precedents)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.56 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_nolab). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology_report, psa_trend, and previous_notes—do not fully answer the moderator's questions regarding the prior biopsy grade (Q1) or the surveillance protocol status (Q2).

ALIGNMENT WITH THE PANEL
The Panel Protocol concludes with BIOPSY based on a weighted vote, but this decision is explicitly contingent on the documented prior grade, which was not recorded in the retrieved documents.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented Gleason or ISUP grade from the prior biopsy? This is not answered by the retrieved documents.
Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due? This is not answered by the retrieved documents.

WHAT CARRIES WEIGHT, AND WHY
The most relevant variables are the rising PSA trend (which suggests progression) and the PI-RADS 4 score, as these factors interact with the EAU guideline regarding repeat biopsy. The lack of explicit surveillance status is critical for determining the urgency of the next step.

MY SUGGESTION TO THE CHAIR
Given that the key variables required by the EAU guideline—the prior biopsy grade and surveillance status—remain unconfirmed by the retrieved records, the decision cannot be definitively made according to the guideline's terms.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Given the rising PSA trend to 7.9 ng/mL and the PI-RADS 4 finding, further investigation is warranted despite the prior positive biopsy. The decision to proceed with a biopsy is supported by the interaction of the rising PSA and the PI-RADS score, which aligns with the need for further histological characterization. The lack of an explicitly documented prior Gleason grade or surveillance status means the evidence converged on the need for a repeat biopsy to clarify the current situation.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
